

Laboratory Bulletin

DATE:	9 June 2025	
TO:	North Zone – All Physicians, Nurses and Managers	
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL)	
	Implementation of High Sensitivity Troponin I (hs-TnI) on the Quidel TriageTrue with 2-hr Chest Pain Pathway in North Zone Rural Sites	

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective June 17, 2025, implementation of a new high sensitivity troponin I (hs-TnI) assay on the Quidel TriageTrue will begin at rural hospitals in the North Zone.
- Labs using TriageTrue hsTnl as their primary testing method will go live on June 17

Primary Method – Go Live June 17				
Boyle	Grande Cache	LaCrete	Smoky Lake	
Elk Point	Grimshaw	Manning	Spirit River	
Fox Creek	Jasper	McLennan	Wabasca	

Labs using TriageTrue hsTnl as their backup testing method will go live on June 19

Backup to Beckman Coulter Access2 – Go Live June 19			
Athabasca	Edson	Hinton	St Paul
Barrhead	Fairview	Lac la Biche	Valleyview
Beaverlodge	Fort Vermilion	Mayerthorpe	Westlock
Bonnyville	High Level	Peace River	Whitecourt
Cold Lake	High Prairie	Slave Lake	

- Sites using the TriageTrue hsTnI assay will offer the new 2-Hour Chest Pain Pathway for Quidel TriageTrue High Sensitivity Troponin-I Assay (Appendix 1).
- The TriageTrue hs-Tnl assay requires sample collection in lavender EDTA blood collection tubes.
 No other sample collection tubes are acceptable.
 - For additional information refer to the APL reference: Order of Draw and Order of Transfer
- This troponin assay change will involve new units of measure, reference interval (i.e. 99th percentile upper reference limit of the assay), reporting limits, rule-in/rule-out chest pain pathway, delta values, critical limits and interpretative comments (Table 2).
- At sites with the TriageTrue hs-Tnl assay, critical troponin concentrations (≥ 60 ng/L) will be phoned to the ordering provider <u>ONLY</u> for troponin samples collected in the outpatient/community setting.
- Lab will not phone troponin results for hospital patients (including ER patients and inpatients).

Background

 Evidence supports that a 2-hour chest pain pathway for TriageTrue hs-Tnl is effective and safe for rule-in/rule-out of acute myocardial infarction (AMI).



• The recommended pathway is consistent with clinical practice guidelines and is recommended by the Cardiovascular Program Improvement and Integration Network (PIN) in consultation with Emergency Medicine PIN and Laboratory Medicine provincially.

Why this is important

- The provincial rural immunoassay analyzer project is a large-scale provincial project that will improve
 access to vital laboratory testing in many of Alberta's rural hospitals and will improve standardization in
 instrumentation and reporting.
- Adoption of the 2-hour hs-Tnl chest pain pathway with rapid rule-in/rule-out is gradually expanding across the province and improving flow of patients through emergency rooms.
- This initiative will reduce the variation of troponin assays and chest pain protocols in the province.
- These changes will assist clinicians with evidence-based interpretation of troponin results and guide optimal patient management.

Action Required

- Collect samples for TriageTrue hs-Tnl in lavender EDTA tubes
- Be familiar with changes in assay reporting, container type and the new 2 hr chest pain pathway.
- Be aware of different troponin assays used within the North Zone.
- Do not interpret results across sites with different assays.

Questions/Concerns

- Cardiovascular PIN Cardiovascular PIN@acutecarealberta.ca
- Dr. Kaila Crawford, Associate Medical Director Rural, North Sector, APL kaila.crawford@aplabs.ca

Approved by

Dr. Kaila Crawford, Associate Medical Director Rural, North Sector, APL kaila.crawford@aplabs.ca



Table 1: Summary of new reporting changes for the TriageTrue hs-Tnl assay

	i-STAT conventional Tnl	TriageTrue hs-Tnl 2- hr Chest Pain Pathway (New)	Notes
Collection Tube	Lithium heparin PST (light green)	Lavender EDTA	
Rapid Chest Pain Pathway	N/A	2-hour	
Reporting Units	ug/L (2 decimals)	ng/L (whole number)	
Reference Interval	<0.04 ug/L	< 21 ng/L	
Critical Value	>0.10 ug/L	≥ 60 ng/L	
Reporting Limits	0.02 to 50 ug/L	2 to 1000 ng/L	
Delta Value None		Reported for 0-2 hour delta	
Comments	Interpretive comments and method identification comments	Pathway interpretative comments and method identification comments	Interpretative comments have changed (Table 2)




Table 2: Interpretative comments reported with Quidel TriageTrue hs-Tnl

hs-Tnl	Comment	Elegging
result (ng/L)	Comment	Flagging
< 4	For patients with a non-ischemic ECG, a Troponin I, High Sensitivity of 3 ng/L or less on presentation is highly sensitive for excluding acute myocardial infarction, provided the specimen was collected more than 3-hours from symptom onset. However, for patients with symptoms less than 3-hours duration or concerning clinical presentations, repeat troponin testing at 2-hours after the initial sample is recommended. Please note that patients with ischemic ECG changes and/or high-risk clinical presentations should be considered for further evaluation irrespective of troponin results.	Normal
4 – 20	Troponin I, High Sensitivity is below the upper reference limit (21 ng/L) and results are not consistent with myocardial infarction (MI) or injury. However, patients with acute symptoms (less than 6-hours) or concerning clinical presentations should undergo repeat troponin testing at 2-hours after the initial sample. - Troponin I, High Sensitivity of 4 ng/L or less on presentation AND a 2-hour delta(change) of 2 ng/L or less is highly sensitive for excluding acute myocardial infarction (MI) - A 2-hour delta (change) of 3-7 ng/L may indicate acute myocardial injury and suggest an additional troponin measurement 4 hours after the initial sample, serial ECG testing and clinical re-evaluation. - A 2-hour delta (change) of 8 ng/L or more suggests an acute myocardial injury and may represent acute myocardial infarction in the appropriate clinical scenario. Please note that patients with ischemic ECG changes and /or high-risk clinical presentations should be considered for further evaluation irrespective of troponin results.	Normal
21 – 59	Troponin I, High Sensitivity has a non-specific/non-diagnostic elevation. Interpretation is highly dependent on clinical presentation and patient history. New elevations are concerning; however, many patients have chronic elevations in troponin and measured concentrations near the patient's baseline are reassuring. However, patients with acute symptoms (less than 6-hours) or concerning clinical presentations should undergo repeat troponin testing at 2-hours after the initial sample. - A 2-hour delta (change) of 2 ng/L or less is highly sensitive for excluding acute myocardial infarction. - A 2-hour delta (change) of 3-7 ng/L may indicate acute myocardial injury and suggest an additional troponin measurement 4 hours after the initial sample, serial ECG testing and clinical re-evaluation. - A 2-hour delta (change) of 8 ng/L or more suggests an acute myocardial injury and may represent acute myocardial infarction in the appropriate clinical scenario. Please note that patients with ischemic ECG changes and /or high-risk clinical presentations should be considered for further evaluation irrespective of troponin results.	High
60	Clear elevation of Troponin I, High Sensitivity consistent with acute myocardial injury or infarction in the appropriate clinical context. Repeat troponin testing at 2-hours after the initial sample may be helpful to assess for ongoing myocardial injury.	Critical



Appendix 1: 2-Hour Chest Pain Pathway for Quidel TriageTrue High Sensitivity Troponin-I Assay





Note:

*For all patients with abnormal hs-cTnl results, check the medical record for prior results. Many patients have stable abnormalities in hs-cTnl and measured concentrations similar to the patient's baseline are reassuring.

Per European Society of Cardiology (ESC) Guidelines and 4th universal definition of MI, if the patient is >6h from symptom onset, has a hs-cTnI <21 ng/L (99th percentile upper reference limit), are pain-free, and have a low-risk presentation, they can be considered ruled out.

However, coronary ischemia has not been definitively excluded and unstable angina must be considered. Disposition after a single hs-cTnl <21 ng/L should only be considered for patients with low-risk clinical presentations who are >6 hours since symptoms onset, and should be used cautiously.

Troponin concentration may be elevated in the presence of kidney dysfunction. Patients with an eGFR <60 and an elevated troponin concentration should undergo serial testing to confirm a rising troponin concentration consistent with myocardial injury. Patients with an eGFR <60 who have troponin concentrations in the rule-out zone can be considered to have myocardial injury safely excluded.

HEART Score Calculation				
		Highly suspicious	2	
History	Moderately suspicious			
		Slightly suspicious	0	
	Significant ST-depression			
ECG	Non-specific repolarization disturbance, LBBB, LVH, Paced		1	
		Normal	0	
	≥ 65 years		2	
Age	45-64 years		1	
	≤ 44 years		0	
	☐ Diabetes ☐ Current smoker	≥ 3 risk factors or history of atherosclerotic disease	2	
Risk	Obesity	1 or 2 risk factors	1	
Factors	Family hx CAD HTN (diagnosed) HL (diagnosed)	No risk factors known	0	
hs-cTnl	> 3x normal limit (64 ng/L or greater) 2			
(peak)	1-3x normal limit (21-63 ng/L) 1			
(peak)	< normal limit (< 21 ng/L) 0			
Total (10 maximum)				
HEART Score Interpretation				
Low Risk				0-3
Moderate Risk			4-6	
High Risk			7-10	